Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2008

View Archived Issues

First clinical data on TH-302 released

Recent Janssen patent divulges novel antiarthritic agents

Anticancer VEGFR/PDGFR tyrosine kinase inhibitor TAK-593 profiled

Pegylated docetaxel demonstrates improved efficacy in xenograft models

Preliminary data reported for ANG-1005 in solid tumors, brain metastases and malignant glioma

AstraZeneca rounds up Q3 activities

NicOx reports favorable blood pressure data for naproxcinod in OA patients

Lytix Biopharma presents preclinical results of novel antibacterial LTX-109

FDA approves Norditropin for children born small for gestational age

Potent antifungal activity shown for a novel sordarin derivative in preclinical testing

Celera and Abbott collaborate to identify pharmacogenomic markers

Mesoblast commences phase I/II allogeneic mesenchymal precursor cell trial

Phase II CERE-110 trial in Alzheimer's disease to be funded by NIH grant

SciClone and Sigma-Tau report phase III HCV trial results with Zadaxin

Therapure Biopharma collaborates with BioVectra

Y's Therapeutics to conduct phase I/II trial of YSCMA in France

Recent Kowa patent reports novel therapeutic agents for lipoprotein disorders

Novel mutilin-quinolone hybrid antibacterial from Kyorin described

Interim data show feasibility of i.v., s.c. PRO-140 for HIV

Complete response submitted to FDA for Sanvar in esophageal bleeding

SurModics acquires drug delivery technology from PR Pharmaceuticals

Invitrogen provides update on merger with Applied Biosystems

Derma Sciences initiates enrollment in phase II study of DSC-127 in diabetic foot ulcers

Sanofi-aventis discontinues rimonabant clinical development

New dopamine/serotonin receptor agonists imparted in recent Atir patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...